Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Aims Exenatide is a glucagon-like peptide 1 (GLP-1) mimetic which induces weight loss predominantly, it is presumed, via decreased food intake. However, circulating GLP-1 is also a determinant of energy expenditure. We sought to quantify the effect of exenatide on energy expenditure (EE) and energy intake. Materials and Methods In this single-center, randomized double-blind placebo controlled trial, we randomized 80 healthy, non-diabetic volunteers with obesity (46 women, age: 34.4±8.7 y, body fat by DXA: 44.2±7.8%) to subcutaneous exenatide 10 μg twice daily or placebo. Subjects were admitted to our clinical research unit for measurement of 24h-EE in a whole-room indirect calorimeter and ad libitum food intake using an automated vending machine paradigm before and after randomization. Furthermore, energy expenditure and ad libitum food intake measures were repeated at 24-week after readmission for 7-day inpatient stay. Body weight was obtained weekly for up to 5 weeks and was recorded at each monthly follow up visit up to 24 weeks. Results Prior to randomization, participants over ate during the 3-day vending machine period in the whole study group (114.6±35.2 %), expressed as percentage of weight maintaining energy needs (WMEN) with those who were eventually randomized to exenatide overeating more (121.6±37.7 %) compared to placebo group (107.6±31.5 %). In the exenatide group, ad libitum absolute energy intake decreased by 1016.1±724.5 kcal/day (95% CI: −1250.9 to −781.2) versus a 245.1±710.5 kcal/day (95% CI: −475.4 to −14.7) decrease in placebo (Δ= −624.8 Kcal/day, p < .0001) whereas the reduction in ad libitum caloric intake relative to WMEN was a more modest 366.8±752.1 kcal/day (95% CI: −614.0 to −119.6) decrease compared to 8.0±860.1 kcal/day (95% CI: −286.8 to 270.8) reduction in placebo (Δ= −382.3 Kcal/day, p = 0.03). The decrease was uniform across all macronutrients groups. No differences in 24hEE or substrate oxidation rates were found. In the exenatide group, body weight decreased more over the 5 weeks (β = −0.039 kg/week, p = 0.02) and was lower compared to placebo at the end of fifth week (−1.48±0.77 kg; 95% CI: −3.02 to 0.05, p = 0.06). At the 24-week follow up, there was no difference in energy intake between exenatide group and placebo group and the treatment group decreased 24-h EE more compared to placebo (β = −160.6 Kcal/day, 95% CI: −307.6 to 13.6, p = 0.03) compared to their pre-randomization measurement. However, this reduction was not present after adjustment for changes in FM and FFM (β = −87 kcal/day, p = 0.14). No difference was observed in body weight (Δ = −1.72 kg, 95% CI: −5.77 to 2.30, p = 0.39) in exenatide versus placebo over 24 weeks. Conclusion Compared with placebo, exenatide decreased early ad libitum energy intake but did not change 24h-EE. However, the reduction was more modest in relative versus absolute terms (i.e. below that needed for WMEN). Thus, although rate of weight change was greater in the exenatide treated subjects at 5 weeks, the absolute difference in weight was not significant. These findings indicate that although exenatide reduces food intake, it may be more beneficial in blunting overeating and thus may serve to more prevent weight regain following initial weight loss. Clinical Trial Registration Numbers NCT00856609; clinicaltrials.gov
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Exenatide is the first short acting GLP-1 agonist approved for treatment of type 2 diabetes mellitus (DM) and has also been shown to induce weight loss in patients with obesity with [2-4] and without diabetes [5, 6] with a large variability (ranging by −0.”
BackgroundDeterminants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber.
Ravussin, E., Lillioja, S., Anderson, T. E., Christin, L., & Bogardus, C. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112749 · Cited by 1,166 · cited 2×
“The CO2 and O2 concentrations of the outflowing air were measured as previously described [21] and calculations of oxygen consumption and carbon dioxide production were used to calculate 24-h respiratory quotient (RQ) and EE [21].”
MethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.162 · Cited by 537
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416 · cited 1×
“The lifestyle counseling was standardized and based on the principles of the diabetes prevention program [19] and which encourage increased physical activity and healthy eating habits.”
MethodFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“GLP-1 infusions reduced resting metabolic rate, diet induced thermogenesis and carbohydrate oxidation in two studies [35, 36], but another study found increased EE via an insulin mediated mechanism [9].”
Result
Research works printed but not linked: 27
- Monami, 2009, Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials, Eur J Endocrinol, 160, 909, 10.1530/EJE-09-0101 · DOI · Paper page
- Buse, 2007, Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials, Clin Ther, 29, 139, 10.1016/j.clinthera.2007.01.015 · DOI · Paper page
- Nelson, 2007, The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes, Diabetes Technol Ther, 9, 317, 10.1089/dia.2006.0024 · DOI · Paper page
- Dushay, 2012, Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes, Diabetes Care, 35, 4, 10.2337/dc11-0931 · DOI · Paper page
- Pannacciulli, 2006, Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans, Am J Clin Nutr, 84, 556, 10.1093/ajcn/84.3.556 · DOI
- Shalev, 1997, Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man, Eur J Clin Invest, 27, 10, 10.1046/j.1365-2362.1997.540613.x · DOI
- Hwa, 1998, Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation, Peptides, 19, 869, 10.1016/S0196-9781(98)00033-3 · DOI
- Flint, 2000, The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans, Int J Obes Relat Metab Disord, 24, 288, 10.1038/sj.ijo.0801126 · DOI
- Sun, 2015, Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis, J Diabetes Res, 2015, 10.1155/2015/157201 · DOI · Paper page
- Abbott, 1988, Short-term energy balance: relationship with protein, carbohydrate, and fat balances, Am J Physiol Endocrinol Metab, 255, E332, 10.1152/ajpendo.1988.255.3.E332 · DOI · Paper page
- Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis, JAMA, 298, 194, 10.1001/jama.298.2.194 · DOI · Paper page
- Thearle, 2013, Extent and determinants of thermogenic responses to 24 hours of fasting, energy balance, and five different overfeeding diets in humans, J Clin Endocrinol Metab, 98, 2791, 10.1210/jc.2013-1289 · DOI
- Pannacciulli, 2007, The 24-h carbohydrate oxidation rate in a human respiratory chamber predicts ad libitum food intake, Am J Clin Nutr, 86, 625, 10.1093/ajcn/86.3.625 · DOI · Paper page
- Piaggi, 2013, Lower "awake and fed thermogenesis" predicts future weight gain in subjects with abdominal adiposity, Diabetes, 62, 4043, 10.2337/db13-0785 · DOI
- Rising, 1992, Food intake measured by an automated food-selection system: relationship to energy expenditure, Am J Clin Nutr, 55, 343, 10.1093/ajcn/55.2.343 · DOI
- Geiselman, 1998, Reliability and validity of a macronutrient self-selection paradigm and a food preference questionnaire, Physiol Behav, 63, 919, 10.1016/S0031-9384(97)00542-8 · DOI
- Venti, 2010, Reproducibility of ad libitum energy intake with the use of a computerized vending machine system, Am J Clin Nutr, 91, 343, 10.3945/ajcn.2009.28315 · DOI
- Drab, 2016, Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a clinical update of safety and efficacy, Curr Diabetes Rev, 12, 403, 10.2174/1573399812666151223093841 · DOI · Paper page
- Edwards, 2001, Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers, Am J Physiol Endocrinol Metab, 281, E155, 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
- Verdich, 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans, J Clin Endocrinol Metab, 86, 4382
- Pinelli, 2011, Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers, J Clin Pharmacol, 51, 165, 10.1177/0091270010367653 · DOI
- Flint, 2013, The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment, Diabetes Obes Metab, 15, 958, 10.1111/dom.12108 · DOI · Paper page
- Madsbad, 2016, Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists, Diabetes, Obesity and Metabolism, 18, 317, 10.1111/dom.12596 · DOI · Paper page
- Deane, 2010, Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia, J Clin Endocrinol Metab, 95, 215, 10.1210/jc.2009-1503 · DOI · Paper page
- Drucker, 1988, Glucagon gene expression in vertebrate brain, J Biol Chem, 263, 13475, 10.1016/S0021-9258(18)68261-4 · DOI · Paper page
- de Fonseca, 2000, Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats, Metabolism, 49, 709, 10.1053/meta.2000.6251 · DOI
- Holmes, 2009, Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions, J Physiol, 587, 4749, 10.1113/jphysiol.2009.175067 · DOI
Cited by
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
Metadata
- Authors
- Basolo, A., Burkholder, J., Osgood, K., Graham, A., Bundrick, S., Frankl, J., Piaggi, P., Thearle, M. S., & Krakoff, J.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 85
- Pages
- 116-125
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2790926033
- Cited by
- 43
- References
- 17
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 267 d)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/j.metabol.2018.03.017
- The paper
- Basolo, A., Burkholder, J., Osgood, K., Graham, A., Bundrick, S., Frankl, J., Piaggi, P., Thearle, M. S., & Krakoff, J. (2018). Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial. Metabolism. https://doi.org/10.1016/j.metabol.2018.03.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.